The European Medicines Agency (EMA) on April 8, 2026, launched a veterinary medicine safety campaign, releasing a 2026 awareness poster aimed at promoting the safe use of veterinary medicinal products across the European Union. The campaign targets veterinarians, animal owners, and national competent authorities, seeking to increase awareness of adverse event reporting and responsible medicine use.
The poster, published by EMA's Veterinary Medicines Division, is part of a broader communication initiative rather than a regulatory action. It does not introduce new binding requirements or numerical targets but serves as an informational tool to complement existing safety monitoring frameworks. The campaign follows the agency's recent focus on drug safety, including the Pharmacovigilance Risk Assessment Committee's (PRAC) adoption of new drug safety monitoring recommendations on April 7, 2026, which proposed stricter reporting requirements for adverse drug reactions and risk management plans for human medicines. While that PRAC opinion targeted human pharmaceuticals, the new veterinary campaign extends similar safety awareness efforts to the animal health sector.
Document Context and Type
The awareness poster is a non-binding communication material, not a formal opinion or guideline. It is issued by EMA's Veterinary Medicines Division, which oversees the evaluation and monitoring of veterinary medicines. The campaign aligns with EMA's broader public engagement strategy, as outlined in its April 7, 2026 report on 2025 public engagement activities, which highlighted initiatives to enhance transparency and stakeholder dialogue, including workshops and public consultations.
Policy Orientations and Trade-offs
The campaign emphasizes the importance of reporting suspected adverse events to improve veterinary pharmacovigilance. This reflects a trade-off between increasing data collection and the administrative burden on veterinarians and animal owners. By encouraging more reporting, the campaign aims to enhance safety monitoring but may require additional effort from stakeholders to comply with reporting procedures. The initiative does not impose new legal obligations but relies on voluntary participation.
Impact on Stakeholders
- Veterinarians: May face increased expectations to report adverse events, potentially adding to administrative workload, but benefit from improved safety data that can inform prescribing practices.
- Animal owners: Gain greater awareness of how to report suspected medicine side effects, empowering them to contribute to safety monitoring, though they may need to invest time in understanding reporting channels.
- National competent authorities: Receive more comprehensive safety data, aiding their regulatory oversight, but may need to allocate resources to handle increased reporting volumes.
- Pharmaceutical companies producing veterinary medicines: Could see enhanced reputation through demonstrated commitment to safety, but may face pressure to proactively monitor and report adverse events.
Expected Institutional Follow-up
The campaign is expected to be disseminated through national authorities and veterinary associations. EMA may evaluate the campaign's impact on reporting rates and consider further awareness initiatives. The agency's ongoing work on veterinary pharmacovigilance, including potential updates to guidelines, could follow, building on the PRAC's recent recommendations for human medicines.